UrgoStart dressings are indicated for the treatment of chronic wounds, such as leg ulcers, pressure ulcers or diabetic foot ulcers, as well as for non-healing acute wounds. The dressings contain a layer of open weave polyester mesh, impregnated with hydrocolloid polymers, within a petroleum jelly.
 
Status In progress
Process MT
ID number 380

Provisional Schedule

Resolution 17 December 2018
Expected publication 31 January 2019

Project Team

Project lead Liesl Millar

Email enquiries

Stakeholders

External assessment group KiTEC
Manufacturers Urgo Ltd
Others Association of British Healthcare Industries (ABHI)
  Association of Healthcare Technology Providers for Imaging, Radiotherapy and Care (AXrEM)
  Birmingham Community Healthcare NHS Trust
  Boston Scientific
  Cornwall Partnership Foundation Trust
  Department of Health & Social Care
  Greater Manchester Health & Social Care Partnership
  Healthcare Improvement Scotland
  Johnson & Johnson Medical Ltd
  Leeds Teaching Hospitals Trust
  Manchester Metropolitan University
  Manchester University NHS FT
  Medicines and Healthcare Products Regulatory Agency
  NHS England
  North West Boroughs Healthcare
  Royal Devon and Exeter Foundation Trust
Professional groups Devices for Dignity
  HealthTech Alliance
  Medical Technology Group
  The British In Vitro Diagnostics Association (BIVDA)
  The Vascular Society

Timeline

Key events during the development of the guidance:

Date Update
16 November 2018 Committee meeting: 2
12 October 2018 - 09 November 2018 Draft guidance
21 September 2018 Committee meeting: 1
22 March 2018 Scope published
19 February 2018 Stakeholder registration opens

For further information on how we develop guidance, please see our page about NICE medical technologies guidance